Novartis has reported new clinical data showing the sustained efficacy and safety offered by Cosentyx in the treatment of psoriasis.
Positive five-year efficacy and safety results have been presented from a phase III long-term extension study in patients with moderate-to-severe plaque psoriasis, showing the drug is able to deliver almost clear or completely clear skin in the majority of patients.
“Novartis has reported new long-term clinical data showing the sustained efficacy and safety of Cosentyx in the treatment of psoriasis.“
Data from this study will be presented at a key medical congress in the second half of 2017, with the positive five-year phase III results set to represent a key milestone in assessing long-term benefits of the treatment.
Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said: "With the first data from a pivotal trial with five years of follow-up, Cosentyx continues to demonstrate it can provide what psoriasis patients want - a life with clear skin."
Recent label updates announced for Cosentyx in Europe have demonstrated the long-term superiority of Cosentyx versus Stelara in moderate-to-severe plaque psoriasis, on the basis of 52-week data from the CLEAR study.
This has allowed the availability of the drug - which was originally launched in 2015 - to be expanded to include the treatment of moderate-to-severe scalp psoriasis.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical